Answers are grounded in this paper and cite their sources.
Shows improved efficacy of adoptive T-cell therapy in cancer, suggesting nicotinamide riboside as a beneficial metabolic adjuvant.
differentiation, in part through a transcriptional program associated with Foxo1, thereby improving the efficacy of adoptive T-cell therapy. These findings identify NR as a promising and translatable metabolic adjuvant for HCC immunotherapy.
No takes yet. Share an insight, caveat, or question.
Pang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: